Hypertrophic Cardiomyopathy: Current Treatment and Future Options

Maron, 2018, Clinical course and management of hypertrophic cardiomyopathy, N Engl J Med, 379, 655, 10.1056/NEJMra1710575 Firth, 2019, Cardiology: hypertrophic cardiomyopathy, Clin Med(Lond), 19, 61 Elliott, 2014, ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 Limongelli, 2013, Skeletal muscle involvement in cardiomyopathies, J Cardiovasc Med (Hagerstown), 14, 837, 10.2459/JCM.0b013e3283641c69 Wilkinson, 2012, Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry, Am Heart J, 164, 442, 10.1016/j.ahj.2012.04.018 Zhang, 2021, Clinical and genetic characteristics of different types of non-obstructive hypertrophic cardiomyopathy, Zhonghua Xin Xue Guan Bing Za Zhi, 49, 593 Veselka, 2017, Hypertrophic obstructive cardiomyopathy, Lancet., 389, 1253, 10.1016/S0140-6736(16)31321-6 Ommen, 2020, AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines, Circulation, 142, e533 Marian, 2017, Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy, Circ Res, 121, 749, 10.1161/CIRCRESAHA.117.311059 Branzi, 1985, Genetic heterogeneity of hypertrophic cardiomyopathy, Int J Cardiol, 7, 129, 10.1016/0167-5273(85)90352-3 Pare, 1961, Hereditary cardiovascular dysplasia. A form of familial cardiomyopathy, Am J Med, 31, 37, 10.1016/0002-9343(61)90222-4 Millat, 2010, Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy, Eur J Med Genet, 53, 261, 10.1016/j.ejmg.2010.07.007 Erdmann, 2003, Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy, Clin Genet, 64, 339, 10.1034/j.1399-0004.2003.00151.x Walsh, 2017, Defining the genetic architecture of hypertrophic cardiomyopathy: re-evaluating the role of non-sarcomeric genes, Eur Heart J, 38, 3461 Walsh, 2017, Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples, Genet Med, 19, 192, 10.1038/gim.2016.90 Afshar, 2017, Return-to-Play in 2017 and the Role of Shared Decision-Making in Patients with Inherited and Acquired Channelopathies and Cardiomyopathies, Curr Treat Options Cardiovasc Med, 19, 75, 10.1007/s11936-017-0574-y Farzam, 2022, Sudden Death in Athletes Shapero, 2022, Experiences of athletes with arrhythmogenic cardiac conditions in returning to play, Heart Rhythm O2, 3, 133, 10.1016/j.hroo.2022.01.009 Drezner, 2021, Return to play with hypertrophic cardiomyopathy: are we moving too fast? A critical review, Br J Sports Med, 55, 1041, 10.1136/bjsports-2020-102921 de Feria, 2020, Applying shared decision making to sports participation for a patient with hypertrophic cardiomyopathy, JACC Case Rep, 3, 6, 10.1016/j.jaccas.2020.11.005 Gersh, 2011, ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 58, 2703, 10.1016/j.jacc.2011.10.825 Ramchand, 2020, Advanced imaging for risk stratification of sudden death in hypertrophic cardiomyopathy, Heart, 106, 793, 10.1136/heartjnl-2019-315176 Nakano, 2018, Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap?, Prog Pediatr Cardiol, 49, 31, 10.1016/j.ppedcard.2018.03.001 Weng, 2016, Prognostic Value of LGE-CMR in HCM: A Meta-Analysis, JACC Cardiovasc Imaging, 9, 1392, 10.1016/j.jcmg.2016.02.031 Greulich, 2021, Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study, Eur Heart J Cardiovasc Imaging, 22, 732, 10.1093/ehjci/jeaa423 Rakesh, 2021, 3D speckle tracking echocardiographic strain pattern in Hypertrophic Cardiomyopathy and its relation with Sudden Cardiac Death risk markers, Indian Heart J, 73, 451, 10.1016/j.ihj.2020.11.144 Choudhury, 2017, Integrated Imaging in Hypertrophic Cardiomyopathy, Am J Cardiol, 119, 328, 10.1016/j.amjcard.2016.09.033 Charron, 1997, Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population, Circulation, 96, 214, 10.1161/01.CIR.96.1.214 Haland, 2020, The role of echocardiography in management of hypertrophic cardiomyopathy, J Echocardiogr, 18, 77, 10.1007/s12574-019-00454-9 2011, 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Thorac Cardiovasc Surg, 142, e153, 10.1016/j.jtcvs.2011.10.020 Gersh, 2011, J Am Coll Cardiol, 58, e212, 10.1016/j.jacc.2011.06.011 Nagueh, 2016, Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, Eur Heart J Cardiovasc Imaging, 17, 1321, 10.1093/ehjci/jew082 Parato, 2016, Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy, Cardiovasc Ultrasound, 14, 30, 10.1186/s12947-016-0072-5 Ho, 2006, A clinician's guide to tissue Doppler imaging, Circulation, 113, e396, 10.1161/CIRCULATIONAHA.105.579268 Notomi, 2006, Enhanced ventricular untwisting during exercise: a mechanistic manifestation of elastic recoil described by Doppler tissue imaging, Circulation, 113, 2524, 10.1161/CIRCULATIONAHA.105.596502 Williams, 2009, Echocardiography in hypertrophic cardiomyopathy diagnosis, prognosis, and role in management, Eur J Echocardiogr, 10, iii9, 10.1093/ejechocard/jep157 Serri, 2006, Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy, J Am Coll Cardiol, 47, 1175, 10.1016/j.jacc.2005.10.061 Zhao, 2013, Real-time three-dimensional echocardiographic assessment of left ventricular diastolic dyssynchrony and dysfunction in hypertrophic cardiomyopathy, Nan Fang Yi Ke Da Xue Xue Bao, 33, 8 Marchesini, 2016, The role of cardiac magnetic resonance imaging in hypertrophic cardiomyopathy, Rev Cardiovasc Med, 17, 57, 10.3909/ricm0811 Rickers, 2005, Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy, Circulation, 112, 855, 10.1161/CIRCULATIONAHA.104.507723 Green, 2012, Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, JACC Cardiovasc Imaging, 5, 370, 10.1016/j.jcmg.2011.11.021 Adabag, 2008, Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance, J Am Coll Cardiol, 51, 1369, 10.1016/j.jacc.2007.11.071 Prinz, 2013, Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy, Can J Cardiol, 29, 358, 10.1016/j.cjca.2012.05.004 Raiker, 2020, Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy, Int J Cardiovasc Imaging, 36, 1147, 10.1007/s10554-020-01808-6 Suk, 2008, Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients, HeartLung Circ, 17, 370 Sivalokanathan, 2022, The role of cardiovascular magnetic resonance imaging in the evaluation of hypertrophic cardiomyopathy, Diagnostics (Basel), 12, 314, 10.3390/diagnostics12020314 Karur, 2018, Use of myocardial T1 mapping at 3.0 T to differentiate anderson-fabry disease from hypertrophic cardiomyopathy, Radiology, 288, 398, 10.1148/radiol.2018172613 Oliveira, 2016, Cardiac magnetic resonance and computed tomography in hypertrophic cardiomyopathy: an update, Arq Bras Cardiol, 107, 163 Langer, 2015, Myocardial fibrosis in hypertrophic cardiomyopathy: volumetric assessment of late enhancement provided by cardiac computed tomography, J Comput Assist Tomogr, 39, 797, 10.1097/RCT.0000000000000272 Chaikriangkrai, 2015, Diagnosis of ischemia in hypertrophic cardiomyopathy: role of computed tomography and nuclear stress testing, Curr Opin Cardiol, 30, 483, 10.1097/HCO.0000000000000201 Tregubova, 2020, Probl Radiac Med Radiobiol, 25, 592, 10.33145/2304-8336-2020-25-592-606 2016, Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012)- digest version, Circ J, 80, 753, 10.1253/circj.CJ-66-0122 Louie, 1994, Hypertrophic cardiomyopathy, Prog Cardiovasc Dis, 36, 275, 10.1016/S0033-0620(05)80036-2 Raj, 2022, Hypertrophic Obstructive Cardiomyopathy. [Updated 2021 Nov 4] Hirota, 1982, A clinical study of left ventricular diastolic properties, Jpn Circ J, 46, 49, 10.1253/jcj.46.49 Carini, 1994, Criteri angiografici per la diagnosi di cardiomiopatia ipertrofica [Angiographic criteria in the diagnosis of hypertrophic cardiomyopathy], G Ital Cardiol, 24, 367 Shariat, 2014, Utility of coronary CT angiography in outpatients with hypertrophic cardiomyopathy presenting with angina symptoms, J Cardiovasc Comput Tomogr, 8, 429, 10.1016/j.jcct.2014.09.007 Heitner, 2019, Lifestyle modification and medical management of hypertrophic cardiomyopathy, Cardiol Clin, 37, 45, 10.1016/j.ccl.2018.08.004 Lundberg, 2008, The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics, Nat Rev Drug Discov, 7, 156, 10.1038/nrd2466 Isbell, 2007, Hemoglobin oxygen fractional saturation regulates nitrite-dependent vasodilation of aortic ring bioassays, Am J Physiol Heart Circ Physiol, 293, H2565, 10.1152/ajpheart.00759.2007 Tafelmeier, 2020, Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy, Clin Cardiol, 43, 430, 10.1002/clc.23346 Cherian, 1966, Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy, Br Med J, 1, 895, 10.1136/bmj.1.5492.895 Cohen, 1967, Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade, Circulation, 35, 847, 10.1161/01.CIR.35.5.847 Edwards, 1970, Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy, Br Heart J, 32, 219, 10.1136/hrt.32.2.219 Goodwin, 1988, Pharmacologic treatment of hypertrophic cardiomyopathy: beta-blockade or calcium blockade or what?, 1, 665 von Dohlen, 1990, Current perspectives in hypertrophic cardiomyopathy: diagnosis, clinical management, and prevention of disability and sudden cardiac death, Clin Cardiol, 13, 247, 10.1002/clc.4960130404 Haberer, 1983, Hypertrophe obstruktive Kardiomyopathie: Spontanverlauf im Vergleich zur Langzeittherapie mit Propranolol und Verapamil [Hypertrophic obstructive cardiomyopathy: spontaneous course in comparison to long-term therapy with propranolol and verapamil], Z Kardiol, 72, 487 Sherrid, 2000, Medical treatment of hypertrophic cardiomyopathy, Curr Cardiol Rep, 2, 148, 10.1007/s11886-000-0012-7 Kaltenbach, 1985, Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms, J Mol Cell Cardiol, 17, 59, 10.1016/0022-2828(85)90009-4 Kaltenbach, 1979, Treatment of hypertrophic obstructive cardiomyopathy with verapamil, Br Heart J, 42, 35, 10.1136/hrt.42.1.35 Hopf, 1987, 10-year results and survival of patients with hypertrophic cardiomyopathy treated with calcium antagonists, Z Kardiol, 76, 137 Rosing, 1980, Verapamil therapy: a new approach to pharmacologic treatment of hypertrophic cardiomyopathy, Chest, 78, 239, 10.1378/chest.78.1.239 Hopf, 1987, Effects of nifedipine and propranolol combined therapy in patients with hypertrophic cardiomyopathy, Z Kardiol, 76, 105 Dimitrow, 1993, Effects on left ventricular function of pindolol added to verapamil in hypertrophic cardiomyopathy, Am J Cardiol, 71, 313, 10.1016/0002-9149(93)90797-G Ommen, 2011, Hypertrophic cardiomyopathy, Curr Probl Cardiol, 36, 409, 10.1016/j.cpcardiol.2011.06.001 Koga, 1992, Therapeutic effect of oral dipyridamole on myocardial perfusion and cardiac performance in patients with hypertrophic cardiomyopathy, Am Heart J, 123, 433, 10.1016/0002-8703(92)90658-I McKenna, 1985, Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia, Br Heart J, 53, 412, 10.1136/hrt.53.4.412 Adler, 2017, Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients, J Am Heart Assoc, 6, 10.1161/JAHA.116.005152 Haruki, 2015, Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide, Heart Vessels, 30, 604, 10.1007/s00380-014-0534-3 Thaman, 2002, Hypertrophic cardiomyopathy: management issues in the new millennium, Curr Cardiol Rep, 4, 226, 10.1007/s11886-002-0055-z Marian, 2009, Contemporary treatment of hypertrophic cardiomyopathy, Tex Heart Inst J, 36, 194 Smith, 2013, Hypertrophic cardiomyopathy: an overview, Crit Care Nurs Clin North Am, 25, 263, 10.1016/j.ccell.2013.02.011 Roberts, 2005, Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy, Circulation, 112, 293, 10.1161/01.CIR.0000146788.30724.0A Ho, 2021, Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial, Nat Med, 27, 1818, 10.1038/s41591-021-01505-4 Liu, 2022, Effects of angiotensin II receptor blockers on ventricular hypertrophy in hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials, Cardiovasc Drugs Ther, 36, 371, 10.1007/s10557-020-07118-2 Tuohy, 2020, Hypertrophic cardiomyopathy: the future of treatment, Eur J Heart Fail, 22, 228, 10.1002/ejhf.1715 Maron, 2018, Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy, JACC Heart Fail, 6, 353, 10.1016/j.jchf.2017.09.011 ten Cate, 2010, Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution, Circ Heart Fail, 3, 362, 10.1161/CIRCHEARTFAILURE.109.862359 Liebregts, 2017, Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of endorsement, J Am Coll Cardiol, 70, 481, 10.1016/j.jacc.2017.02.080 Faber, 1998, Z Kardiol, 87, 191, 10.1007/s003920050171 Tsuchikane, 2003, Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy, Circ J, 67, 763, 10.1253/circj.67.763 Osman, 2019, Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta-analysis, Clin Cardiol, 42, 190, 10.1002/clc.23113 Liebregts, 2015, A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy, JACC Heart Fail, 3, 896, 10.1016/j.jchf.2015.06.011 Pelliccia, 2021, Septal ablation versus surgical myomectomy for hypertrophic obstructive cardiomyopathy, Curr Cardiol Rep, 23, 165, 10.1007/s11886-021-01600-5 Gharibeh, 2022, Comprehensive left ventricular outflow tract management beyond septal reduction to relieve obstruction, Asian Cardiovasc Thorac Ann, 30, 43, 10.1177/02184923211034689 Yang, 2020, Efficacy and safety of radiofrequency ablation for hypertrophic obstructive cardiomyopathy: A systematic review and meta-analysis, Clin Cardiol, 43, 450, 10.1002/clc.23341 Lawrenz, 2004, Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy, Z Kardiol, 93, 493 Maron, 2000, Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy, N Engl J Med, 342, 365, 10.1056/NEJM200002103420601 Maron, 2007, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, 298, 405, 10.1001/jama.298.4.405 Maron, 2022, Hypertrophic cardiomyopathy: new concepts and therapies, Annu Rev Med, 73, 363, 10.1146/annurev-med-042220-021539 Heitner, 2019, mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial, Ann Intern Med, 170, 741, 10.7326/M18-3016 Olivotto, 2020, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 396, 759, 10.1016/S0140-6736(20)31792-X Ho, 2020, Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 75, 2649, 10.1016/j.jacc.2020.03.064 Desai, 2022, Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy, J Am Coll Cardiol, 80, 95, 10.1016/j.jacc.2022.04.048 Abraham T, Friedman M. Results from cohorts 1 and 2. in: oral presentation, ase 2022 annual scientific session. 2022. Available at:https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-additional-data-redwood-hcm-presented. Accessed November 28, 2022. Siegall J. Cytokinetics announces start of SEQUOIA-HCM, a phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Available at: https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-start-sequoia-hcm-phase-3-clinical-trial. Accessed November 28, 2022. Olivotto, 2018, Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: The RESTYLE-HCM randomized, double-blind, placebo-controlled study, Circ Heart Fail, 11, 10.1161/CIRCHEARTFAILURE.117.004124 Olivotto, 2016, Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial, Circ Heart Fail, 9, 10.1161/CIRCHEARTFAILURE.115.002764 Andries, 2018, Novel pharmacotherapy in hypertrophic cardiomyopathy, Cardiol Rev, 26, 239, 10.1097/CRD.0000000000000211 Lehman, 2022, Targeting the sarcomere in inherited cardiomyopathies, Nat Rev Cardiol, 19, 353, 10.1038/s41569-022-00682-0 Packard, 2022, Contemporary therapies and future directions in the management of hypertrophic cardiomyopathy, Cardiol Ther, 11, 491, 10.1007/s40119-022-00283-5 Bello, 2022, Mavacamten. 2022 Sep 13 Anderson, 2018, Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers, Proc Natl Acad Sci U S A, 115, E8143, 10.1073/pnas.1809540115 Chuang, 2021, Discovery of aficamten (CK-274), a Next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy, J Med Chem, 64, 14142, 10.1021/acs.jmedchem.1c01290 Coppini, 2013, Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy, Circulation, 127, 575, 10.1161/CIRCULATIONAHA.112.134932 Gentry, 2016, Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME), J Am Coll Cardiol, 68, 1815, 10.1016/j.jacc.2016.07.758 Rastegar, 2017, Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience, Ann Cardiothorac Surg, 6, 353, 10.21037/acs.2017.07.07 Vanderlaan, 2017, Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience, Ann Cardiothorac Surg, 6, 364, 10.21037/acs.2017.05.12 Maron, 2014, Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014, Circulation, 130, 1617, 10.1161/CIRCULATIONAHA.114.011580 Chan, 2014, Angiographic and echocardiographic correlates of suitable septal perforators for alcohol septal ablation in hypertrophic obstructive cardiomyopathy, Can J Cardiol, 30, 912, 10.1016/j.cjca.2014.04.008 Maron, 2011, Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy, Circulation, 124, 40, 10.1161/CIRCULATIONAHA.110.985812 Silbiger, 2016, Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy: echocardiographic, pathophysiologic, and surgical insights, J Am Soc Echocardiogr, 29, 622, 10.1016/j.echo.2016.03.003 Sherrid, 2016, The mitral valve in obstructive hypertrophic cardiomyopathy: a test in context, J Am Coll Cardiol, 67, 1846, 10.1016/j.jacc.2016.01.071 Cooper, 2016, Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound® technology to guide ablation, Europace, 18, 113, 10.1093/europace/euv302 Kong, 2021, A modified endocardial radiofrequency ablation approach for hypertrophic obstructive cardiomyopathy guided by transthoracic echocardiography: a case series, Ann Transl Med, 9, 1006, 10.21037/atm-21-2783 Lawrenz, 2011, Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients, J Am Coll Cardiol, 57, 572, 10.1016/j.jacc.2010.07.055 Riedlbauchová, 2013, Ablation of hypertrophic septum using radiofrequency energy: an alternative for gradient reduction in patient with hypertrophic obstructive cardiomyopathy?, J Invasive Cardiol, 25, E128 Szumowski, 2016, Endocardial radiofrequency ablation for septal hypertrophy, Kardiol Pol, 74, 700, 10.5603/KP.2016.0103 Aksu, 2017, Endocardial septal ablation for hypertrophic obstructive cardiomyopathy, Turk Kardiyol Dern Ars, 45, 67 Lawrenz, 2021, Acute and chronic effects of endocardial radiofrequency ablation of septal hypertrophy in HOCM, J Cardiovasc Electrophysiol, 32, 2617, 10.1111/jce.15203 Liu, 2021, Selective interventricular septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy: who can benefit?, Front Cardiovasc Med, 8, 10.3389/fcvm.2021.743044 Liu, 2018, Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy, J Am Coll Cardiol, 72, 1898, 10.1016/j.jacc.2018.07.080 Zhou, 2022, Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy, JAMA Cardiol, 7, 529, 10.1001/jamacardio.2022.0259 Hong, 2016, Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures, J Am Coll Cardiol, 68, 1497, 10.1016/j.jacc.2016.07.735 Wong, 2018, Killing two birds with one stone-MitraClip for flail P2 and systolic anterior motion of mitral valve: a case report, Eur Heart J Case Rep, 2, yty146 Sorajja, 2016, First Experience With Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy, J Am Coll Cardiol, 67, 2811, 10.1016/j.jacc.2016.03.587 Schäfer, 2015, Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip, EuroIntervention, 11, 942, 10.4244/EIJY14M08_13 Sorajja, 2018, Maneuvers for technical success with transcatheter mitral valve repair, Catheter Cardiovasc Interv, 92, 617, 10.1002/ccd.26899 Schäfer, 2014, MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy, Heart Lung Circ, 23, e131, 10.1016/j.hlc.2014.01.007 Thomas, 2017, The use of mitraclip for symptomatic patients with hypertrophic obstructive cardiomyopathy, Cardiology, 137, 58, 10.1159/000454800 Long, 2020, Use of mitraclip to target obstructive sam in severe diffuse-type hypertrophic cardiomyopathy: case report and review of literature, J Invasive Cardiol, 32, E228 Lucarelli, 2022, Transcatheter mitral valve repair for the treatment of severe mitral regurgitation and exertional pre-syncope in a patient with non-obstructive hypertrophic cardiomyopathy: a case report, Eur Heart J Case Rep., 6, ytab446, 10.1093/ehjcr/ytab446 Enriquez, 2014, Management of hypertrophic cardiomyopathy, Ann Glob Health, 80, 35, 10.1016/j.aogh.2013.12.004 Lind, 2006, Genetic basis of hypertrophic cardiomyopathy, Expert Rev Cardiovasc Ther, 4, 927, 10.1586/14779072.4.6.927 Alcalai, 2008, Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics, J Cardiovasc Electrophysiol, 19, 104, 10.1111/j.1540-8167.2007.00965.x Musunuru, 2017, The recent history and perspective in cardiovascular diseases, J Am Coll Cardiol., 70, 2808, 10.1016/j.jacc.2017.10.002 Lopes, 2013, A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations, Heart, 99, 1800, 10.1136/heartjnl-2013-303939 Ma, 2017, Correction of a pathogenic gene mutation in human embryos, Nature, 548, 413, 10.1038/nature23305 Filipowicz, 2013, 221 Jiang, 2013, Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy, Science, 342, 111, 10.1126/science.1236921 Dainis, 2020, Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes, Physiol Genomics, 52, 293, 10.1152/physiolgenomics.00021.2020 Skrzynia, 2009, Genetic counseling and testing for hypertrophic cardiomyopathy: an adult perspective, J Cardiovasc Transl Res, 2, 493, 10.1007/s12265-009-9127-4 Taddei-Allen, 2021, Hypertrophic cardiomyopathy considerations for the managed care pharmacist, Am J Manag Care, 27, S118